- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 38/20 - Interleukines
Détention brevets de la classe A61K 38/20
Brevets de cette classe: 4342
Historique des publications depuis 10 ans
206
|
268
|
256
|
328
|
417
|
419
|
498
|
447
|
448
|
115
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
Iovance Biotherapeutics, Inc. | 301 |
78 |
Massachusetts Institute of Technology | 9795 |
52 |
The Regents of the University of California | 18943 |
48 |
The Board of Trustees of the Leland Stanford Junior University | 6054 |
45 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
42 |
University of Pittsburgh - Of the Commonwealth System of Higher Education | 2912 |
42 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
41 |
Altor BioScience, LLC | 63 |
38 |
Novartis AG | 11238 |
37 |
Nektar Therapeutics | 503 |
32 |
Bristol-myers Squibb Company | 5080 |
30 |
Genentech, Inc. | 3742 |
29 |
The Trustees of the University of Pennsylvania | 4122 |
29 |
Genexine, Inc. | 101 |
27 |
Memorial Sloan-Kettering Cancer Center | 1789 |
27 |
Modernatx, Inc. | 1181 |
27 |
Cytune Pharma | 37 |
26 |
Amgen Inc. | 3779 |
25 |
Regeneron Pharmaceuticals, Inc. | 3650 |
25 |
Board of Regents, The University of Texas System | 5370 |
24 |
Autres propriétaires | 3618 |